|Number of pages||2|
|Journal||The Lancet Infectious Diseases|
|State||Published - Oct 2017|
This output contributes to the following UN Sustainable Development Goals (SDGs)
Access to Document
Other files and links
Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae – Authors' reply. / Gutiérrez-Gutiérrez, Belén; Bonomo, Robert A.; Carmeli, Yehuda et al.In: The Lancet Infectious Diseases, Vol. 17, No. 10, 10.2017, p. 1020-1021.
Research output: Contribution to journal › Comment/debate
TY - JOUR
T1 - Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae – Authors' reply
AU - Gutiérrez-Gutiérrez, Belén
AU - Bonomo, Robert A.
AU - Carmeli, Yehuda
AU - Paterson, David L.
AU - Pascual, Alvaro
AU - Rodríguez-Baño, Jesús
N1 - Funding Information: JRB has been a scientific advisor for AstraZeneca, Merck, and InfectoPharm in research projects, and has been speaker at accredited educational courses funded by unrestricted grants from Merck. RAB received grants for research from NIH, Veteran Affairs, Allergan, Merck, Roche, Wockhardt, and Entasis. YC received grants, honoraria, travel support, consulting fees, and other forms of financial support from Achaogen, Allecra Therapeutics, AstraZeneca, Basilea Pharmaceutica, Biomerieux, Cepheid, DaVolterra, Durata Therapeutics, Intercell AG, Merck, PPD is not an acroninum, is the name of a company, as stated. So no definition possible., Proteologics, Rempex Pharmaceuticals, Rib-X Pharmaceuticals, Syntezza Bioscience, and Takeda Pharmaceutical. DLP has received honoraria for advisory board participation from Merck, AstraZeneca, Cubist, Pfizer, and Novartis. AP has been a speaker for Merck and B Braun; he has been scientific advisor for Merck and has received unrestricted research grants from B Braun and AstraZeneca . DLP has been on advisory boards for Merck, Shionogi, GSK, Meiji, Achaogen, and Pfizer, and has grant support from Merck. BGG declares no competing interests.
PY - 2017/10
Y1 - 2017/10
UR - http://www.scopus.com/inward/record.url?scp=85032000489&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(17)30522-4
DO - 10.1016/S1473-3099(17)30522-4
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???
C2 - 28948921
AN - SCOPUS:85032000489
SN - 1473-3099
VL - 17
SP - 1020
EP - 1021
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 10